A medium-sized group of clinics enters into a five-year agreement with a care-coordination platform vendor, only to spend eighteen months and $400,000 developing workarounds for an unsupported workflow that the vendor never intended to cover. This is the real-world build-or-buy scenario facing most health tech teams: not custom vs. off-the-shelf, but which billable hours they are willing to pay.
The hidden cost structure of off-the-shelf healthtech platforms
Per seat or per patient pricing seems reasonable until you consider a platform accessing thousands of patients' data where it becomes extremely expensive. The vendors are aware of that, and the different pricing tiers assume that switching costs would prevent any changes despite growth eating away at the initial value proposition.
Data portability proves to be a test for this assumption. Migrating the clinical data out of the proprietary format, and particularly migrating the data with custom fields accumulated over time, can become a separate project with limited motivation from the vendor side to facilitate it.
Customization ceiling can be subtle. A platform works perfectly for 90% of the clinical process but encounters the wall when dealing with 10% left, the very part that makes this workflow unique to your clinic. This issue is aggravated by the integration with EHR/EMR systems not natively supported by the vendor which usually leads to introducing some sort of middleware that needs additional maintenance. Updates for HIPPA, HL7 and FHIR compliance also come on the vendors' roadmap.
Where custom software actually earns back its upfront cost
Upfront costs for custom builds are real and will often be bigger than what was originally budgeted for by the team. ROI is achieved in three to five years as licensing costs tied to patient volumes are cut down and workflow-specific efficiencies increase to minimize staff time spent on workflow activities not supported by off-the-shelf solutions.
Owning the data architecture means a lot more than many realize. This means a change in product direction, a new integration, or even a regulatory requirement does not become dependent on the vendor's priority to accommodate you.
When certain criteria are met, custom builds become less valuable against their off-the-shelf counterparts. These include low patient volumes, early stage product validation, and non-core administrative tools which require no customization or product differentiation. For time-to-value as well, an off-the-shelf solution wins out over a custom build. An off-the-shelf solution is up and running within weeks while a custom build takes months.
Compliance and quality assurance: the cost center nobody budgets for
Healthtech QA is not simply traditional software QA with added documentation. It involves regulatory audit trails, HIPAA-compliant data privacy testing, and interoperability testing for HL7/FHIR standards that most traditional QA processes simply weren't designed to perform.
In terms of costs, it's a huge imbalance. In the event of a compliance problem discovered post-launch, the costs include regulatory fines, hurried efforts to do remediation work, and damage to reputation through your hospital system partners, while discovering the same problem in pre-launch QA means you pay a tiny fraction of that cost.
If you purchase, you transfer some of that compliance risk to the vendor. If you build, you transfer it all back to yourself, which is why many healthtech companies won't even try to build that capability internally. Rather than building deep regulatory-testing expertise from a standing start, many teams turn to QA staff augmentation companies that already specialize in regulated environments, which shortens the learning curve on compliance-specific testing considerably.
Team structure and delivery model as an ROI variable
The party who actually develops the software has an impact on the cost and speed of development as much as the decision of whether to build or buy. In-house developers provide the closest communication feedback but have the full cost burden of salaries and benefits.
Nearshore markets have become a common answer to this trade-off. Teams that hire software developers in Argentina often cite overlapping working hours with U.S.-based clinical and product teams as the deciding factor over cheaper but less synchronous alternatives.
It is common practice to understaff a custom build in order to cut costs, but understaffing leads to technical debt, which slows down every other feature going forward and ultimately makes the organization spend even more on rebuilding the solution. Structure-related choices made in this context live far beyond the launch date itself.
A practical framework for making the build-vs-buy call
Prior to deciding, determine the portion of the software which is unique to the workflow compared to being able to be substituted with a competitor's technology stack. Determine the degree of risk for regulation, and determine the rate at which the patient volume growth is forecasted to exceed the threshold where licensing becomes unfeasible. A combination model frequently solves the false dilemma of buy or build: buy the commodity pieces such as scheduling and billing, while building the clinical workflow which makes the product unique. The warning signs of the product becoming a burden within 18 months include recurring custom-field hacks, requests for integration which are not being prioritized by the vendor, and updates to the compliance which lag behind the audit schedule.
Conclusion
The build-or-buy choice is not so much about cost at a particular point in time. It is rather about who, you or the supplier, has control over the product’s roadmap with regard to the elements of the product that are important to the patients and doctors.
